NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in virtual care, today announced that it issued an inducement award to a new employee.
Effective November 1, 2025, in connection with commencing employment as Chief Technology Officer, Dave Ross was granted an award of restricted stock units covering 86,906 shares of Teladoc Health’s common stock, par value $0.001 per share (“Common Stock”), and an award of performance stock units covering a target of 86,906 shares of Common Stock (for which up to 173,812 shares may be earned). The restricted stock units vest, based on continued service to Teladoc Health, as to one-third of the underlying shares on the first anniversary of the grant date, with the remainder vesting quarterly over two years thereafter. The performance stock units provide a target number of shares of Common Stock that would be earned over three years based on various financial metrics. The award was approved by the Compensation Committee of the Board of Directors of Teladoc Health and was granted under the Teladoc Health, Inc. 2023 Employment Inducement Incentive Award Plan as an employment inducement award pursuant to New York Stock Exchange Rule 303A.08.
About Teladoc Health
Teladoc Health (NYSE: TDOC) is the global leader in virtual care. The company is delivering and orchestrating care across patients, care providers, platforms, and partners — transforming virtual care into a catalyst for how better health happens. Through our relationships with health plans, employers, providers, health systems and consumers, we are enabling more access, driving better outcomes, extending provider capacity and lowering costs. Learn more at teladochealth.com.
Media:
Lou Serio
202-569-9715
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$7.05 |
| Daily Change: | 0.05 0.71 |
| Daily Volume: | 5,732,199 |
| Market Cap: | US$1.250B |
November 18, 2025 October 29, 2025 October 14, 2025 August 14, 2025 July 29, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load